AbstractObjective To observe the clinical effect of Tongxinluo Capsules combined with Sacubitril and Valsartan in the treatment of pulmonary hypertension due to left heart disease (PH-LHD). Methods A total of 108 patients with PH-LHD who admitted in our hospital from August to December 2019 were selected and randomly divided into the control group, the observation group A and the observation group B, with 36 cases in each group. Three groups were given routine treatment, the control group was given Valsartan based on routine treatment, the observation group A was given Sacubitril and Valsartan based on routine treatment, and the observation group B was treated with Sacubitril and Valsartan combined with Tongxinluo Capsules based on routine treatment. After treatment for 3 months, the clinical efficacy, arterial partial pressure of oxygen (PaO2), pulmonary arterial pressure (pulmonary arterial systolic pressure[PASP], pulmonary arterial diastolic pressure [PADP]) were compared among the three groups. Results The effective rate of the observation group B were higher than those of the observation group A and the control group, the differences were statistically significant (P＜0.05). The level of PaO2 in the three groups after treatment were higher than those before treatment, the differences were statistically significant (P＜0.05). The level of PaO2 in the observation group B was higher than that in the observation group A and the control group, the differences were statistically significant (P＜0.05).After treatment, the level of PASP and PADP of the three groups were lower than those before treatment, the differences were statistically significant (P＜0.05). The levels of PASP and PADP in the observation group B were lower than those in the observation group A and the control group, the differences were statistically significant (P＜0.05). Conclusion Tongxinluo capsule combined with Sacubitril and Valsartan in the treatment of PH-LHD can increase clinical efficacy, and improve PaO2 and pulmonary arterial pressure, which is worthy of clinical promotion and application.
